Changes in Beneficial Ownership · 4
Allurion Technologies, Inc.
Changes in Beneficial Ownership
Structured filing — 4
form4-07232026_090723.xml
Filing details
- Report period
- 2026-07-21
- Issuer
- ALLURION TECHNOLOGIES, INC.
- Issuer CIK
- 0001964979
- Trading symbol
- ALUR
- No longer subject to Section 16
- Checked
Reporting owner 1
- Name
- RTW INVESTMENTS, LP
- Reporting owner CIK
- 0001493215
- Relationship
- 10% owner
- Address
- 40 10TH AVENUE, 7TH FLOOR, NEW YORK, NY, 10014
Reporting owner 2
- Name
- WONG RODERICK
- Reporting owner CIK
- 0001493280
- Relationship
- 10% owner
- Address
- 40 10TH AVENUE, 7TH FLOOR, NEW YORK, NY, 10014
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value per share | 2026-07-21 | J · Form 4[F1] | 209,254 | D | [F1] | 0 | I | See footnotes[F2][F3] |
| Common Stock, $0.0001 par value per share | 2026-07-21 | J · Form 4[F4] | 161,807 | D | [F4] | 0 | I | See footnotes[F2][F5] |
| Common Stock, $0.0001 par value per share | 2026-07-21 | J · Form 4[F6] | 19,934 | D | [F6] | 0 | I | See footnotes[F2][F7] |
| Common Stock, $0.0001 par value per share | 2026-07-21 | J · Form 4[F8] | 1,771 | D | [F8] | 0 | I | See footnotes[F2][F9] |
Table key
- J · Form 4
- Other acquisition or disposition; see explanation
- D
- Disposed
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Funded Warrant (Right to Buy) | 0.0001 | 2026-07-21 | J · Form 4[F1] | 209,254 | A | [F1] | [F10] | [F10] | Common Stock | 209,254 | 209,254 | I | See Footnotes[F2][F3] |
| Pre-Funded Warrant (Right to Buy) | 0.0001 | 2026-07-21 | J · Form 4[F4] | 161,807 | A | [F4] | [F10] | [F10] | Common Stock | 161,807 | 161,807 | I | See footnotes[F2][F5] |
| Pre-Funded Warrant (Right to Buy) | 0.0001 | 2026-07-21 | J · Form 4[F6] | 19,934 | A | [F6] | [F10] | [F10] | Common Stock | 19,934 | 19,934 | I | See footnotes[F2][F7] |
| Pre-Funded Warrant (Right to Buy) | 0.0001 | 2026-07-21 | J · Form 4[F8] | 1,771 | A | [F8] | [F10] | [F10] | Common Stock | 1,771 | 1,771 | I | See footnotes[F2][F9] |
Table key
- J · Form 4
- Other acquisition or disposition; see explanation
- A
- Acquired
- I
- Indirect
Footnotes
- F1
- On July 21, 2026, RTW Master Fund, Ltd. ("Master Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a "Pre-Funded Warrant").↩ 1↩ 2↩ 3↩ 4
- F2
- RTW Investments, LP (the "Adviser") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. ("RTW Innovation"), RTW Biotech Opportunities Operating Ltd. ("RTW Biotech Fund") and other funds or accounts managed by the Adviser (each, an "Other RTW Fund"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
- F4
- On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 161,807 shares of the Issuer's Common Stock.↩ 1↩ 2↩ 3↩ 4
- F6
- On July 21, 2026, RTW Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of the Issuer's Common Stock.↩ 1↩ 2↩ 3↩ 4
- F8
- On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock.↩ 1↩ 2↩ 3↩ 4
- F10
- The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
Remarks
On June 18, 2026, the Issuer effected a 1-for-15 reverse stock split. The share counts herein reflect the reverse stock split.
Signature 1
- Signed
- /s/ Roderick Wong, M.D. - For RTW Investments, L.P., By: Roderick Wong, M.D., Managing Partner
- Date
- 2026-07-23
Signature 2
- Signed
- /s/ Roderick Wong, M.D.
- Date
- 2026-07-23
Filed exhibits
- EX-24 ↗ex24-07232026_090723.htm
Company context
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Smart Capsule, the world’s first and only swallowable, ProcedurelessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Smart Capsule is an investigational device in the United States.
Current securities
Recent company filings
- 25-NSE - filed by NEW YORK STOCK EXCHANGE LLC regarding ALLURION TECHNOLOGIES, INC.Oct 13, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 24, 2026
- NT 10-Q filingAug 14, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesJul 24, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 23, 2026